{"data":{"id":"us-ky/krs-218a.511","jurisdiction":"us-ky","citation":"KRS 218A.511","heading":"Definitions for KRS 218A.511 to 218A.519.","body":"As used in KRS 218A.511 to 218A.519:\n(1) \"Department\" means the Department of Agriculture;\n(2) \"Drug developer\" means a for -profit, nonprofit, or public benefit corporation\nengaged in drug development and manufacturing that has established an ibogaine\ndrug development agreement with at least one (1) additional state with a plan to\nconduct drug development clinical trials to obtain United States Food and Drug\nAdministration approval for use of ibogaine; and\n(3) \"Ibogaine\":\n(a) Means a crystalline alkaloid psychogenic compound obtained from the\nTabernanthe iboga plant; and\n(b) Includes any of its derivatives or analogs in any form, whether existing or as -\nyet to be developed.","path":["KRS Chapter 218A"],"source_url":"https://apps.legislature.ky.gov/law/statutes/statute.aspx?id=57904","current_through":"Includes enactments through the 2026 Regular Session","vintage":"09/05/2026","retrieved_at":"2026-09-05T20:52:31Z","sha256":"9f4b2a5e55192e76f2d26624c85ccb67dd0dd1eea9849caa7a5659a378cfe024","source_id":"us-ky","stale":false,"prev":"us-ky/krs-218a.510","next":"us-ky/krs-218a.513"},"notice":"GroundRules: Original legal text. Not legal advice."}